RVMD Trading Analysis - 10/26/2026 11:48 AM — TRU-SENTIMENT

News Headlines & Context

Recent general-knowledge context for Revolution Medicines (RVMD) suggests the following themes that may be relevant to the trading data observed:

• RVMD is a clinical-stage oncology company; recent pipeline updates on RAS(ON) inhibitor candidates have historically driven volatility.
• No confirmed near-term earnings date in provided data, but fiscal year end is 2025-12-01 per fundamentals, implying annual reporting cycles.
• Biotech sector sentiment has been sensitive to broader risk-on/risk-off moves given high beta (1.82).
• General news of clinical trial progress could act as a catalyst; however, negative trial readouts or dilution concerns are typical bearish risks.
• Headlines of institutional accumulation (52.9% institutional ownership) may align with bullish options flow seen in embedded sentiment data, while weak technicals reflect recent price drawdown from September highs.

This news context is separated from the strict data-driven analysis below.

Fundamental Analysis

Based strictly on the provided FUNDAMENTALS data for RVMD:

• Trailing EPS is -8.84; company is not profitable (no positive earnings).
• Trailing PE, forward PE, PEG ratio, price-to-book, profit margins, ROE, debt-to-equity, and free cash flow are all null/unavailable in data.
• Revenue total, revenue growth, and analyst target mean price are null; no analyst consensus provided.
• Market cap is $39,712,174,080.00 with shares outstanding of 214,336,000.00.
• Dividend yield is 0.00; no dividend.
• 52-week high is $224.31, low is $53.67 — wide range indicating high speculative volatility.
• Institutional ownership is 52.91%; beta is 1.82 (elevated systematic risk).
• Historical volatility is 47.66%; average volume is 2,109,000.00.

Fundamentally, the lack of earnings and revenue data shows a pre-profit biotech. This diverges from bullish options sentiment but aligns with bearish technicals (price below SMAs, RSI weak).

Current Market Position

From embedded data: Daily close on 2026-10-23 was $188.10 (per indicators current_price $188.10). Minute bars show 2026-10-26 11:20 close at $185.28, down from early 2026-10-23 14:30 close $188.16.

Intraday on 2026-10-26: opened weak at $183.77 by 11:00, recovered to $185.28 by 11:20, indicating minor late-morning bounce.

Technical Analysis

Price is below SMA 5 ($190.15), SMA 20 ($195.32), and SMA 50 ($201.72) — bearish alignment, no bullish crossover. RSI 37.40 shows weak momentum near oversold. MACD negative with histogram -0.67 confirms bearish pressure. Bollinger mid $195.32, price near lower half; 30-day range $175.91–$211.51, price at ~43% of range.

True Sentiment Analysis (Delta 40-60 Options)

From embedded True Sentiment Options data (2026-10-26 11:47):

Call Volume: $295,050.00 (62.6%) Put Volume: $176,430.00 (37.4%) Total: $471,480.00

Sentiment is Bullish based on delta 40-60 directional conviction. Call contracts 240 vs put 52. This shows bullish near-term positioning despite bearish technicals — a divergence noted in option spread recommendation (no trade advised).

Key Price Levels (Observational Only)